663 / 1068
- Proven dose-effect response in
RT+CHT regimens… boosting the
tumor/mesorectum may increase pCR
and major response rates
- Toxicity limits: exploring feasible
protocols
- Exploiting acceleration (importance of
Adaptive RT: background I
repopulation) …reducing treatment time,
Hyper/hypo in combination with IMRT
(?)
- Evidence of relevant shrinkage during
RT+CHT (especially in regimens
including oxaliplatin), visible with MRI
- Can we exploit T shrinkage to safely
boost the residual T ?
Appelt 2012